Imipenem-cilastatin in the treatment of hospital infections.
Imipenem was tested on 65 gram-negative bacterial strains consecutively isolated in patients affected by hospital infection and used as empiric therapy in 52 patients presenting a hospital infection suspected of gram-negative origin. More than 96% of the tested strains resulted sensitive to imipenem. This antibiotic showed a good clinical result in more than 80% of the cases when used as therapy. Therefore imipenem could be considered the drug of first choice in patients with a severe prognosis and a nosocomial infection suspected to be due to a gram-negative microorganism.
Mao
P
P
Istituto di Chirurgia d'Urgenza, Università di Torino, Italy.
Enrichens
F
F
Olivero
G
G
Sciascia
C
C
Benedetto
G
G
Franchello
A
A
Olivero
S
S
D015377:Cilastatin / Q000494:pharmacology*; D003428:Cross Infection / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D015378:Imipenem / Q000494:pharmacology*; D011379:Prognosis; D011480:Protease Inhibitors / Q000494:pharmacology*; D013845:Thienamycins / Q000494:pharmacology*; D016896:Treatment Outcome
D011480:Protease Inhibitors; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem